ERBB2 and neoplasm: As a derivative of Irinotecan, DXd is a topoisomerase I inhibitor that mediates anti-tumor activity by inhibiting DNA transcription and replication of tumor cells, which is also clinically-used in DS8201, another HER2-targeted ADC35.